In this video, Motley Fool health-care analyst Max Macaluso takes a closer look at the leadership of Amarin (NASDAQ:AMRN), maker of the triglyceride-lowering blockbuster drug Vascepa, and tells you what you need to know about leadership when considering whether to buy. Amarin's current CEO, Joseph Zakrzewski, has an ironic twist in his past that gives him key insight into Vascepa's biggest competitor. Since many consider Amarin to be a potential buyout target, Zakrzewski's unique knowledge will give him an edge if options like that come to the table.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/18/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.